News
HKEX launches market consultation to enhance listing framework competitiveness
2026-03-13
On March 13, Hong Kong Exchanges and Clearing (HKEX) published a consultation paper as the first phase of its listing framework competitiveness review. Proposals include lowering the market capitalisation threshold for weighted voting rights (WVR) listings from HK$40 billion to HK$20 billion, easing secondary listing requirements for overseas-listed issuers, and extending confidential filing to all new applicants. The consultation runs until May 8.
Overview
On March 13, 2026, The Stock Exchange of Hong Kong, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing (HKEX), published a consultation paper as the first phase of its review of the competitiveness of Hong Kong's listing framework. The main proposals include easing the listing requirements for issuers with weighted voting rights (WVR), lowering the thresholds for secondary listings by overseas-listed issuers, and extending confidential filing to all new applicants. The consultation period is eight weeks and ends on May 8, 2026.
Background
In its 2018 listing reforms, HKEX introduced listings for companies with WVR structures, for pre-revenue biotech companies (Chapter 18A) and a framework for secondary listings of overseas-listed issuers. In 2023 it added a listing route for specialist technology companies (Chapter 18C). Katherine Ng, HKEX's Head of Listing, said the new proposals build on the success of the 2018 reforms and follow extensive engagement with stakeholders. This paper is only the first phase; proposals on other reforms are to be set out in later consultation papers.
Key Points
| Item | Current | Proposed |
|---|---|---|
| WVR market capitalisation test | At least HK$40 billion, or at least HK$10 billion plus revenue of at least HK$1 billion | At least HK$20 billion, or at least HK$6 billion plus revenue of at least HK$600 million |
| Weighted voting ratio cap | 10:1 | Up to 20:1 where market capitalisation at listing is at least HK$40 billion |
| Minimum WVR shareholding | Generally 10% | At least 5% if the stake is worth at least HK$4 billion at listing |
| Secondary listing of non-WVR issuers (Test B) | Market capitalisation of HK$10 billion | Market capitalisation of HK$6 billion |
- Innovativeness: The "innovative company" test would be refined to give non-tech issuers with new business models a path to WVR listing, and qualified biotech and specialist technology companies would be presumed innovative.
- Conversion to primary listing: The requirements for converting a secondary listing to a (dual) primary listing would be redrafted, with added guidance on typical compliance steps.
- Accounting standards: The US GAAP waiver would be extended to subsidiaries of US-listed parents and companies with substantial US operations, and the requirement to revert to HKFRS or IFRS after a US delisting would be removed.
- Chapters 18A and 18C: Commercialised biotech and specialist technology companies would be allowed to use the specialist routes even if they meet an ordinary financial eligibility test.
- Confidential filing: Confidential filing, currently available to eligible secondary listing applicants, biotech and specialist technology companies and others, would be extended to all new applicants. Where an application that is not substantially complete is returned, the identities and roles of the professional parties responsible for the application materials, not only the sponsor, would be published.
- Ownership continuity and control: Existing guidance would be codified so that an applicant meets the requirement if there was no material change in influence over management during the relevant period, even if ownership changed.
Implications for Markets and Companies
If the financial thresholds for WVR and secondary listings are lowered, companies that were previously too small to qualify may gain the option of a Hong Kong listing. The wider availability of confidential filing may affect how companies plan their listing preparations, particularly those that wish to manage the timing of public disclosure during the application stage.
For companies already listed in the United States or mainland China, for growth companies that wish to preserve founder control, and for overseas companies including Japanese firms, the proposals may serve as a reference when assessing the role of the Hong Kong market. It should be noted, however, that these are consultation proposals only, and the final rules may change depending on the feedback received.
Outlook and Schedule
The consultation closes on May 8, 2026. HKEX is expected to decide on the final rule amendments and their effective date in light of the responses, but no effective date has been announced so far. Proposals for the second and later phases of the review are also expected to be published.
Comment from TAKARA
TAKARA continuously monitors developments in listing rules in Hong Kong and other overseas markets. For companies considering a Hong Kong listing, we can help organise information in light of the rule changes and provide support for listing preparation procedures.
This article provides general information based on published materials and news reports. It is not a solicitation or recommendation of any financial product and does not constitute investment advice.


